Study Summary
This trial will test whether the dietary supplement nicotinamide riboside (NR) can improve heart function in heart failure patients by increasing levels of the metabolite nicotinamide adenine dinucleotide (NAD+).
Eligible Conditions
- Heart Failure
- Metabolic Disorders
- Systolic Heart Failure
- Chronic Heart Failure (CHF)
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 7 Secondary · Reporting Duration: Up to 14 days
Up to 14 days
Between-group comparisons of inflammatory markers in blood
Between-group comparisons of inflammatory markers in myocardium
Between-group comparisons of myocardial NAD(H) levels
Between-group comparisons of myocardial gene expression by RNA-seq and the myocardial epigenome by ATAC-seq
Between-group comparisons of myocardial mitochondrial morphology.
Between-group comparisons of myocardial mitochondrial respiratory function.
Between-group comparisons of myocardial protein acetylation
Between-group comparisons of whole blood NAD+ levels
Correlations of myocardial NAD(H) levels with measures
Correlations of whole blood NAD+ levels with measures
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
Nicotinamide riboside
1 of 2
Placebo
1 of 2
Experimental Treatment
Non-Treatment Group
40 Total Participants · 2 Treatment Groups
Primary Treatment: Nicotinamide riboside · Has Placebo Group · Phase < 1
Nicotinamide riboside
Drug
Experimental Group · 1 Intervention: Nicotinamide riboside · Intervention Types: DrugPlacebo
Other
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: OtherTreatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nicotinamide riboside
Not yet FDA approved
Trial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 14 days
Who is running the clinical trial?
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,593 Previous Clinical Trials
46,945,806 Total Patients Enrolled
University of WashingtonLead Sponsor
1,597 Previous Clinical Trials
1,569,109 Total Patients Enrolled
Kevin D O'Brien, MDPrincipal InvestigatorUniversity of Washington
2 Previous Clinical Trials
38 Total Patients Enrolled
Eligibility Criteria
Age 18+ · All Participants · 5 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:You are scheduled for elective LVAD implantation.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Conditions
Cancer Related
Treatments